KYMR
Kymera Therapeutics Inc
112.40$
+2.8%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Kymera Therapeutics Inc (KYMR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -54 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12 | -11 | -12 | -11 | 132 | -20 | -23 | -31 | -37 | -38 | -40 | -39 | -34 | -40 | -44 | -35 | -32 | 8.0 | -40 | -43 | -50 | -62 | -79 | -60 | -27 | -67 | -89 | -54 | -237 | |
| 0.2 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 0.9 | 1.5 | 1.9 | 2.0 | 2.0 | 2.0 | 2.1 | 2.1 | 2.0 | 2.0 | 2.0 | 8.2 | |
| 0.2 | 0.3 | 0.4 | 0.7 | 2.3 | 1.8 | 3.2 | 5.7 | 7.4 | 8.7 | 7.9 | 9.6 | 9.1 | 8.9 | 9.4 | 11 | 12 | 11 | 12 | 14 | 15 | 14 | 14 | 15 | 16 | 14 | 16 | 19 | 65 | |
| 0.3 | 0.4 | 0.5 | 0.6 | 2.4 | 3.4 | 4.5 | 7.0 | 9.1 | 8.7 | 7.9 | 10 | 9.1 | 8.9 | 9.4 | 9.8 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -1.6 | -0.1 | -2.0 | 1.4 | 137 | -11 | -15 | -13 | -18 | -15 | -13 | -0.2 | 1.4 | 2.2 | -8.1 | 8.0 | 9.8 | -0.5 | 1.9 | 11 | 1.4 | 3.4 | -27 | 1.4 | 38 | 5.8 | -35 | -11 | -2.1 | |
| 0.2 | 0.2 | 1.4 | 3.9 | 2.4 | 1.4 | 0.2 | 0.6 | 0.3 | 0.5 | 0.5 | 0.7 | 1.2 | 0.4 | 4.0 | 11 | 8.1 | 12 | 7.4 | 4.7 | 0.2 | 0.9 | 0.5 | 0.7 | 0.2 | 0.1 | 0.4 | 0.5 | 1.2 | |
| -78 | 62 | -37 | -47 | -334 | -4.0 | 44 | 61 | -137 | -68 | 26 | 82 | -37 | -50 | 25 | 36 | 61 | 19 | -331 | 16 | -158 | 69 | 49 | 60 | -235 | -394 | -143 | 20 | -752 | |
| – | – | – | – | – | – | 0.8 | 1.8 | 3.3 | 2.2 | 0.4 | 0.6 | 1.0 | 2.3 | 1.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.2 | -0.2 | -0.2 | -0.4 | -0.2 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | -0.3 | – | – | – | – | -0.6 | -0.3 | -0.3 | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -1.7 | |
| 0.0 | 21 | 93 | -0.4 | 196 | 0.3 | 0.6 | 1.6 | 246 | 2.1 | 0.2 | 0.4 | 150 | 2.0 | 1.2 | 1.3 | -0.2 | 1.9 | 354 | 1.4 | 251 | 2.8 | 0.3 | 246 | 40 | 705 | 19 | 14 | 778 | |
| -91 | 72 | 44 | -59 | -6.4 | -24 | 22 | 32 | 72 | -104 | -14 | 43 | 79 | -87 | -18 | 1.9 | 29 | 29 | -16 | -26 | 43 | 9.5 | -30 | 246 | -223 | 244 | -213 | -20 | -211 | |
| -13 | -11 | -13 | -15 | 129 | -22 | -23 | -31 | -38 | -39 | -41 | -40 | -36 | -40 | -48 | -46 | -40 | -3.6 | -47 | -48 | -50 | -63 | -80 | -61 | -27 | -67 | -89 | -55 | -238 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.